A lovelly day in Sydney, working in the office, another 20 hours. Getting so many things sorted for the business and family.
these studies are so good, they came in today, very exciting.
study hard, have hope, the cure is here. I have faith. Some of these drugs are available germany at friendly prices! I feel optomistic, despite a few cells.
I started back on xeloda today, wonderful. just wonderful.
no bites from 60 minutes, or abc. I better make my money some other way, which I am doing.
these studies are so good, they came in today, very exciting.
study hard, have hope, the cure is here. I have faith. Some of these drugs are available germany at friendly prices! I feel optomistic, despite a few cells.
I started back on xeloda today, wonderful. just wonderful.
no bites from 60 minutes, or abc. I better make my money some other way, which I am doing.
4 Conclusions
In this study we show that local reduction of DCs mediated by iNKT cells regulates the response to immunotherapy in a mouse model of aggressive breast cancer. The elimination of APC that cross-present tumor-derived antigens in dLNs was shown previously to be one mechanism of immunosuppression mediated by Tregs [26]. However, iNKT cells were believed to consistently perform anti-tumor activities, while immunosuppressive functions were ascribed to the non-invariant subset of NKT cells [59]. Here we demonstrate for the first time a novel mechanism of immune escape mediated by iNKT cells.
These results have important implications for the design of immunotherapies targeting iNKT cells (reviewed in [58]). CD1d blockade, or the iNKT-depleting antibody NKTT120 recently developed for inflammatory diseases [60], could have a role in treatment of cancers in which iNKT acquire immunosuppressive functions.
| 11:43 PM (5 hours ago)  | | ||
The following new articles have just been published in Journal for ImmunoTherapy of CancerFor articles using Author Version-first publication you will see a provisional PDF corresponding to the accepted manuscript. In these instances, the fully formatted Final Version PDF and full text (HTML) versions will follow in due course. | ||
Research article  Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcomeNishino M, Giobbie-Hurder A, Ramaiya NH, Hodi FJournal for Immunotherapy of Cancer 2014, 2 :40 (18 November 2014) Abstract | Full Text | PDF | PubMed Research article iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccineCorgnac S, Perret R, Zhang L, Mach J, Romero P, Donda AJournal for ImmunoTherapy of Cancer , $article.articleCitationInfo. Abstract | Provisional PDF Research article Detailed characterization of tumor infiltrating lymphocytes in two distinct human solid malignancies show phenotypic similarities.Kovacsovics-Bankowski M, Chisholm L, Vercellini J, Tucker CG, Montler R, Haley D, Newell P, Ma J, Tseng P, Wolf R, Vetto J, Hammill C, Hansen P, Weinberg ADJournal for ImmunoTherapy of Cancer , $article.articleCitationInfo. Abstract | Provisional PDF Case report Ipilimumab in patients with melanoma and autoimmune diseaseKyi C, Carvajal RD, Wolchok JD, Postow MAJournal for Immunotherapy of Cancer 2014, 2 :35 (14 October 2014) Abstract | Full Text | PDF | PubMed Case report Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case seriesRavi S, Spencer K, Ruisi M, Ibrahim N, Luke JJ, Thompson JA, Shirai K, Lawson D, Bartell H, Kudchadkar R, Gunter N, Mehnert JM, Lipson EJJournal for Immunotherapy of Cancer 2014, 2 :33 (14 October 2014) Abstract | Full Text | PDF | PubMed Research article Invariant natural killer T cells regulate anti-tumor immunity by controlling the population of dendritic cells in tumor and draining lymph nodesPilones KA, Aryankalayil J, Babb JS, Demaria SJournal for Immunotherapy of Cancer 2014, 2 :37 (14 October 2014) Abstract | Full Text | PDF | PubMed Research article Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapyMandl SJ, Rountree RB, dela Cruz TB, Foy SP, Cote JJ, Gordon EJ, Trent E, Delcayre A, Franzusoff AJournal for Immunotherapy of Cancer 2014, 2 :34 (14 October 2014) Abstract | Full Text | PDF | PubMed Research article Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8+ T cellsPollack SM, Jones RL, Farrar EA, Lai IP, Lee SM, Cao J, Pillarisetty VG, Hoch BL, Gullett A, Bleakley M, Conrad EU, Eary JF, Shibuya KC, Warren EH, Carstens JN, Heimfeld S, Riddell SR, Yee CJournal for Immunotherapy of Cancer 2014, 2 :36 (14 October 2014) Abstract | Full Text | PDF | PubMed | ||
The following new supplement has just been published in Journal for ImmunoTherapy of Cancer | ||
Volume 2 Suppl 3 (6 November 2014) Meeting abstracts National Harbor, MD, USA. 6-9 November 2014 | ||
